Fig. 6.

AC-4–130 decreases tumor formation and leukemogenesis in vivo. a Tumor volume of MV4–11 cells subcutaneously injected into both flanks of Rag2^−/−γc^−/− recipients, treated daily with vehicle or AC-4–130 (25 mg/kg). b Immunoblot showing pY-STAT5 and STAT5 levels after treatment. β-ACTIN was used as loading control. Uncropped version of the Western blot is shown in Supplementary Fig. 9. c H&E staining, Ki67, and PDGFRβ immunohistochemical staining of subcutaneously grown tumors